$CLYM

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing a 29-day half-life, 90% APRIL suppression, and 60-75% IgA suppression. The drug was well-tolerated. Phase 2 trial data is expected in H1 2027, with Phase 3 initiation planned for 2027. The company will host a webcast on September 3.

Climb Bio, Inc. (CLYM) shares rose 17% after reporting positive Phase 1 trial results for CLYM116, its anti-APRIL monoclonal antibody. The drug showed near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression, with a half-life of 29 days. The trial enrolled 46 subjects and reported no serious adverse events. The company plans to present additional data in Q4 2026 and anticipates Phase 2 trial results in H1 2027.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d92589dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT SM June 12, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Climb Bio, Inc., a Delaware corporation (the “ Company ”), proposes, subject to the terms and conditions

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-99.1 2 d72849dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 CLIMB BIO, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS: July 26, 2021 APPROVED BY THE STOCKHOLDERS: July 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Pla

This article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activities. The report also compares CEO compensation to market averages and outlines the company's financial data as of December 2025.

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy ...

Here is how Climb Bio, Inc. (CLYM) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

WELLESLEY HILLS, Mass., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 ...